Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Vestn Oftalmol ; 133(6): 138-148, 2017.
Artigo em Russo | MEDLINE | ID: mdl-29319681

RESUMO

An assessment of economic burden of Diabetic Macular Edema (DME) in Russian Federation was conducted on the example of four pilot regions including Samara Region, Republic of Bashkortostan, Chuvash Republic and Yaroslavl Region. The assessment involved a newly developed interactive pharmacoeconomic model that uses data from questionnaire surveys of leading DME experts residing in the regions. In the course of the study, direct and indirect costs associated with DME were calculated. The highest direct costs of DME treatment were seen in the Republic of Bashkortostan - 302 482 RUB/year per patient. Direct cost of treating a single DME patient in the Samara Region was 34 271 RUB/year, in the Yaroslavl Region - 32 308 RUB/year and in the Chuvash Republic - 12 243 RUB/year. Indirect costs per DME patient in the Samara Region amounted to 67 530 RUB/year, in the Yaroslavl Region - 75 177 RUB/year, in the Republic of Bashkortostan - 102 884 RUB/year and in the Chuvash Republic - 81 082 RUB/year. Total annual costs per DME patient in the Samara Region was 101 801 RUB/year, in the Yaroslavl Region - 107 485 RUB/year, in the Republic of Bashkortostan - 405 366 RUB/year and in the Chuvash Republic - 93 325 RUB/year.


Assuntos
Inibidores da Angiogênese , Retinopatia Diabética , Fotocoagulação a Laser , Inibidores da Angiogênese/economia , Inibidores da Angiogênese/uso terapêutico , Efeitos Psicossociais da Doença , Custos e Análise de Custo , Retinopatia Diabética/economia , Retinopatia Diabética/epidemiologia , Retinopatia Diabética/terapia , Humanos , Fotocoagulação a Laser/economia , Fotocoagulação a Laser/estatística & dados numéricos , Federação Russa/epidemiologia
2.
Vestn Oftalmol ; 130(1): 37-41, 2014.
Artigo em Russo | MEDLINE | ID: mdl-24684064

RESUMO

Antivasoproliferative therapy is a pathogenetic treatment for diabetic macular edema. The objective of the study was to investigate the effect of ranibizumab on foveolar parameters in spongiform macular edema. A total of 37 patients (38 eyes) with spongiform macular edema were assessed and given antivasoproliferative therapy with ranibizumab. Optical coherence tomography showed a reduction of the total retinal thickness by 44 microm (from 306 +/- 77 microm to 262 +/- 30 microm, p < 0.05). The pigment epithelium thickness within the central area changed from 21 +/- 4 microm to 40 +/- 9 microm. The maximum decrease of the outer nuclear layer thickness was noted in 400 +/- 100 microm from foveola and averaged from 72 +/- 19 microm to 29 +/- 6 microm with its gradual increase to the periphery to 100 +/- 8 microm.


Assuntos
Anticorpos Monoclonais Humanizados/administração & dosagem , Macula Lutea/patologia , Edema Macular/patologia , Feminino , Angiofluoresceinografia , Seguimentos , Fundo de Olho , Humanos , Injeções Intravítreas , Edema Macular/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Ranibizumab , Tomografia de Coerência Óptica , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...